Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation

Hanan Alkhaldia University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USAView further author information

Danielle Sewellc Translational Genomics Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USAView further author information

Yi Ningd Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USAView further author information

Michael E. Kallend Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USAView further author information

Ashkan Emadia University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA;c Translational Genomics Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USAView further author information

Nancy M. Hardya University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USAView further author information

Maria R. Baera University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USACorrespondence[email protected]
View further author information

show all

Click to increase image sizeClick to decrease image size

Disclosure statement

The authors declare no competing financial interests.

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

Supported by NIH-NCI Grant P30 CA134274 and University of Maryland, Baltimore UMMG Cancer Research Grant #CH 649 CRF issued by the State of Maryland Department of Health and Mental Hygiene (DHMH) under the Cigarette Restitution Fund Program.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation

Information for

Open access

Opportunities

Help and information

Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation

Disclosure statement

Correction Statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature